

## Anti-inflammatory effect of yoghurt in an experimental inflammatory bowel disease in mouse

Nadia Gobbato<sup>1</sup>, Mirta Rachid<sup>1</sup> and Gabriela Perdigón<sup>1,2\*</sup>

<sup>1</sup>Instituto de Microbiología “Dr. Luis C. Verna”, Facultad de Bioquímica, Química y Farmacia, Universidad Nacional de Tucumán. Ayacucho 471-2° piso. Tucumán (4000). Argentina

<sup>2</sup>Centro de Referencia para Lactobacilos – CERELA – CONICET Chacabuco 149. Tucumán (4000). Argentina

Received 20 August 2007; accepted for publication 23 July 2008

Inflammatory bowel disease (IBD; Crohn’s disease and ulcerative colitis) is the clinical outcome of three interactive pathogenic factors: genetic susceptibility, environmental triggers and immune dis-regulation. At present, only the immune response is targeted by most therapeutic or preventive strategies. The beneficial effect of yoghurt on health as well as its immunomodulator effect on the gut immune system is well documented. The aim of this work was to study the possible beneficial effects of yoghurt consumption on an experimental model of IBD in mice. Balb/c mice were fed with yoghurt for 10 consecutive days. At the end of the feeding period the mice received three inoculations of 2, 4, 6-trinitrobenzene sulphonic acid (TNBS) solutions once a week for 3 consecutive weeks. After TNBS instillation the mice received yoghurt again for 10 consecutive days. IBD control received only TNBS. After treatments we analysed the number of IgA-secreting cells, CD4+, CD8+ T cells population and the number of apoptotic cells in the large intestine. The number of erythrocytes and leucocytes in peripheral blood mononuclear cells (PBMCs) was also determined. We demonstrated the antiinflammatory effect of yoghurt in an experimental model of IBD induced by TNBS. The effect was mediated by an increase in the number of the IgA+ cells, a decrease in CD8+ population and by the induction of apoptosis of the infiltrative cells in the large intestine.

**Keywords:** inflammatory bowel disease- yoghurt-TNBS- apoptosis.

The term “inflammatory bowel disease” (IBD) refers primarily to two major disorders, ulcerative colitis (UC) and Crohn’s disease (CD). Both entities are chronic conditions characterized by recurrent inflammatory lesions involving the gut mucosa. Although UC and CD show a considerable degree of etiological and epidemiological similarities, their pathology is entirely different. Ulcerative colitis is essentially a disease involving only the mucosa and the inflammatory disorder is limited to the large intestine. Crohn’s disease is a transmural inflammatory process involving the intestinal wall, from mucosa to serosa, and may affect any point along the gastrointestinal tract from the mouth to the rectum (Steidler, 2001).

Although the pathophysiology of IBD remains the subject of much debate, recent experimental and clinical

studies suggest that the initiation and pathogenesis of these diseases are a confluence of multifactorial events involving interactions among genetic susceptibility, altered mucosal immunity and environmental challenges, mostly related to the acquisition and establishment of the enteric microflora (Fiocchi, 1998; Shanahan, 2001).

The concept that the cause of IBD is immunological arose from the observation that IBD is characterized by massive cellular infiltrates and is associated with abnormalities of the immune system that include inappropriate production of antibodies and T-cell dysfunctions. An imbalance in T-helper cells (Th1 and Th2) differentiates CD from UC on an immunological basis. In UC an over expression of Th2 type cytokines (IL-4, IL-5) has been demonstrated, whereas in CD, Th1 type cytokines such as IFN- $\gamma$  predominate as well as IL-12 produced by macrophages (Blumberg & Strober, 2001; Steidler, 2001).

Animal models of IBD have been useful in potential therapeutic strategies because IL-12 drives Th1 responses.

\*For correspondence; e-mail: perdigon@cerela.org.ar

Several animal models with 2, 4, 6-trinitrobenzene sulphonic acid (TNBS)-induced colitis and treated with anti IL-12 showed that treatment was effective to ameliorate the disease (Fuss et al. 1999). This model of inflammation is associated with a Th1 response.

Intestinal T-lymphocytes are hyperactive in IBD. Pirzer et al. (1991) showed that local tolerance mechanisms are abrogated in Crohn's disease. Patients with UD or UC show an impaired tolerance towards commensal bacteria of the resident microbiota. These findings suggest that commensal bacteria present in the intestinal lumen might induce immune-inflammatory responses that could damage the intestinal mucosa. The intestinal inflammation is accompanied by an imbalance in the microflora and a strong inflammatory response might be mounted toward the gut microbiota, leading to perpetuation of the inflammation and gut barrier dysfunction. These pathologies are treated with anti-inflammatory drugs or surgery.

Current research is addressed to the identification of probiotics strains for bacterial antagonism therapies. Probiotics are live microbial food supplements or components of bacteria which have been shown to have beneficial effects on human health (Guarner & Schaafsma, 1998; Salminen et al. 1998). A recent experimental study has shown that colonization with a *Lactobacillus reuteri* strain can prevent the development of colitis in genetically susceptible mice (Madsen et al. 1999).

Some probiotics may naturally exhibit anti-inflammatory properties when interacting with the human gut mucosa (Salminen et al. 1998). In our laboratory, we demonstrated that conventional yoghurt may exert antitumour activity by a decrease in the inflammatory immune response (Perdigón et al. 2002) and that the dietary supplementation of yoghurt may also play a role in modulating cell proliferation, inducing apoptosis during the development of colorectal carcinoma (Rachid et al. 2002). In normal hosts yoghurt was able to stimulate the immune cells associated with the gut (Perdigón et al. 1994).

Many papers have reported the possible mechanisms underlying the beneficial effects of probiotics in IBD although the observations in some of them are controversial (Guarner & Schaafsma, 1998). The main role of probiotic bacteria would be to counteract the inflammatory process by stabilizing the gut microbial environment and the intestine permeability barrier, with an improvement in the gut immunological barrier, particularly the IgA responses (Isolauri et al. 2001). The probiotic effect may also be mediated *via* control of the balance between pro- and anti-inflammatory cytokines (Isolauri, 2001); thus, probiotics may offer a valuable tool for the prevention and control of inflammatory bowel diseases. As there are no reports concerning the prevention or alleviation of IBD using conventional yoghurt, the present work was carried out to study whether or not yoghurt administration has an effect on the amelioration of colitis induced by TNBS in mice.

## Materials and methods

### Animals

Six- to eight-week-old random-bred BALB/c mice, each weighing 28–30 g, were obtained from the random-bred closed colony kept of our institution (Instituto de Microbiología, Facultad de Bioquímica, Química y Farmacia, Universidad Nacional de Tucumán). Each experimental group consisted of 20 mice (5 for each experimental period). Five mice were also used as normal controls in each assay. All animals received standard pelleted chow and tap water *ad libitum*. They were used under the current laws for animal studies in our Institute of Microbiology.

### Yoghurt preparation

A simulated commercial yoghurt was prepared from a stock culture of lactic acid bacteria containing *Lactobacillus delbrueckii* subsp. *bulgaricus* and *Streptococcus thermophilus*. These strains, mixed at a 1:1 ratio, were incubated in 10% non fat milk at 37 °C for 4 h and then at 4 °C for 24 h. At the end of this process the total bacterial count was  $2 \times 10^8$  cell/ml. Yoghurt was prepared every 24 h to insure that the numbers of bacteria were constant during the time of experimentation.

### Colitis induction

Colitis was induced in mice as described by Chin et al. 1994 with TNBS. Briefly, after overnight fasting, mice were anesthetized by intraperitoneal injection of Pentothal Sodico (Tiopental Sodico) (Abbott Laboratories, Abbott Park, Illinois) (USA) (70 mg/Kg). A 100 µl enema of TNBS solution (Sigma Chemical Co., St. Louis, MO) at a dose of 20 mg/kg in 40% ethanol was instilled for 1 min into the colonic lumen by the anal route. 1 ml syringe fitted with a polyethylene cannula. After instillation the mouse was held by the tail in a vertical position for 30 seconds.

### Feeding procedure and TNBS administration

Four groups of animals were used in the study.

**Group 1:** Normal controls (C): animals given no treatment and fed *ad libitum* with a balanced diet. Animals were sacrificed on the 4th week, coinciding with the end of the experiment for the rest of the group.

**Group 2:** Colitis control (TNBS): the animals were instilled in the colonic lumen with TNBS solution once a week for 3 consecutive weeks and fed *ad libitum* with a balanced diet. The samples were taken once a week for 4 weeks after the last TNBS instillation. Samples were taken on weeks 1, 2, 3 and 4.

**Group 3:** Control yoghurt (Y): the mice were given 3 ml yoghurt as a dietary supplement for 10 consecutive days. This period of yoghurt administration was determined in our laboratory as the optimal dose to stimulate gut immunity (Perdigón et al. 1994). This group did not receive TNBS instillation. Yoghurt was not supplemented during the 3 weeks corresponding to TNBS administration. Then yoghurt was administered again for 10 consecutive days. The samples for this group were taken on week 4.

**Group 4:** Test group (Y-TNBS-Y): before colitis induction, mice were given a daily supplement of 3 ml yoghurt for 10 consecutive days. At the end of the feeding period, the mice received 3 inoculations of 20 mg TNBS solution/kg body weight once a week for 3 consecutive weeks. After TNBS instillation, this group again received a daily supplement of 3 ml yoghurt for 10 consecutive days. The samples were taken on weeks 1, 2, 3 and 4.

#### *Determination of peripheral blood mononuclear cells (PBMCs)*

These determinations were performed once a week during 4 weeks only for the TNBS and Y-TNBS-Y groups. In group 1 and 3 the samples were taken at the end of the experiment on week 4. Blood was collected from 10 mice by heart puncture. The number of erythrocytes and leucocytes was determined by the haemocytometric method and expressed as  $\text{mm}^3$ . Smears stained with Giemsa solution were examined to differentiate between granulocyte, lymphocyte and monocyte populations. They were expressed as percentages.

#### *Histological studies*

Five mice from groups 2 and 4 were killed by cervical dislocation on the 1st, 2nd, 3rd and 4th week. The large intestine was carefully removed and prepared for histological and immunological evaluation, fixed with formalin 10%, dehydrated and embedded in paraffin using standard methods (Sainte Marie, 1962). Serial paraffin sections of 4  $\mu\text{m}$  were cut from each tissue and stained with haematoxylin-eosin for microscopic examination.

#### *Determination of the number of IgA+, CD4+ and CD8+ cells population*

The number of IgA-secreting cells, CD4+ and CD8+ T population was determined from histological samples of large intestine using direct immunofluorescence assay.

The number of IgA secreting cells was measured using  $\alpha$ -chain monospecific antibodies conjugated with fluorescent isothiocyanate isomer (Sigma). Monoclonal antibodies (MAbs) specific for CD4 or CD8 T-lymphocytes-FICT conjugate (Gibco BRD Life Technologies, Buenos Aires, Argentina) were used to determine these populations.

Samples were incubated with 0.2 ml of the antibody diluted 1:100 for IgA and 1:50 for T cells for 30 min at room temperature and then washed three times (10 min each time) with 0.01 M-phosphate-buffered saline, pH 7.2. The results were expressed as the number of positive cells in ten colonic crypts of the large intestine.

#### *Apoptosis determination*

Apoptosis was evaluated on histological slices of the large intestine from each group of animals. The presence of DNA breaks was detected *in situ* by TUNEL test using fluorescein in a Promega apoptosis detection system kit (Madison, WI) (Rachid et al. 2002). It is based on the specific binding of terminal deoxynucleotidyl transferase to the 3'-OH ends of DNA, ensuring the synthesis of a polydeoxynucleotide polymer. The fluorescein-12-dUTP nick end-labelled DNA can be visualized directly by fluorescence microscopy. The cells were defined as apoptotic if the whole nuclear area of the cell labelled positively fluorescent. The number of apoptotic cells was determined by counting 30 fields at 40 $\times$  magnification using a fluorescence microscope.

#### **Statistical Analysis**

Results are expressed as means  $\pm$  SD. Student's test and ANOVA test were used to assess the statistical significance among groups.

#### **Results**

##### *Determination of peripheral blood mononuclear cells (PBMCs)*

We observed a marked increase in polymorphonuclear cells and in the number of total leucocytes. From the 2nd week after inoculation of TNBS, in the TNBS group, relative to the Y-TNBS-Y group. The values obtained with the Y-TNBS-Y group were similar to the control animals during the period assayed. These results are shown in Table 1.

##### *Histological studies*

In TNBS group the large intestine showed changes as early as assay (week 1). These changes continued increasing until week 4 with a distortion of crypts, loss of the histological structure, great infiltration of mononuclear cells in the colonic interstitium, and focal ulcers with an acute inflammatory cell exudates and/or the presence of mucosal edema. (Fig. 1b).

In the control group Y the large intestine did not show histological modifications throughout of feeding period. The test group Y-TNBS-Y showed an improved histological structure of the large intestine compared with TNBS group

**Table 1.** Study of haematological modifications in mice from groups TNBS and Y-TNBS-Y. For normal control the values were: total leucocytes/cm<sup>3</sup> 6000, comprising polymorphonuclear cells 20%, monocytes 4%, lymphocytes 76%. Normal controls are animals given no treatment and eating a conventional balanced diet throughout. For group Y the values were: total leucocytes/cm<sup>3</sup> 7000, comprising polymorphonuclear cells 25%, monocytes 5%, lymphocytes 70%

Time of weeks	Blood cells	TNBS	Y-TNBS-Y
1	Total leucocytes/cm <sup>3</sup>	8000	4000
	Polymorphonuclear, %	20	20
	Monocytes, %	5	5
	Lymphocytes, %	75	75
2	Total leucocytes/cm <sup>3</sup>	11 000	5000
	Polymorphonuclear, %	55	30
	Monocytes, %	2	5
	Lymphocytes, %	43	70
3	Total leucocytes/cm <sup>3</sup>	13 000	6000
	Polymorphonuclear, %	60	28
	Monocytes, %	3	5
	Lymphocytes, %	37	67
4	Total leucocytes/cm <sup>3</sup>	12 000	7000
	Polymorphonuclear, %	57	25
	Monocytes, %	3	5
	Lymphocytes, %	40	70

with a moderate infiltration of mononuclear cells. This result is expressed in Fig. 1c.

#### *Determination of the number of IgA-producing cells, CD4+ and CD8+ T population*

Figure 2 and Fig. 3a & b show the IgA producing cells in the large intestine. There was an increase in the number of IgA producing cells in the group Y-TNBS-Y in relation to the group TNBS during weeks 1 and 2, non-significant differences were found on week 3 and 4 for both groups. Values for the group Y did not show significant differences from the untreated control.


CD4+ T cells were increased in group Y in relation to the untreated control. For the Y-TNBS-Y group values for CD4+ were lower than the TNBS group in the 1st, 3rd and 4th weeks of treatment. In the second week the results were similar to the TNBS group, Fig. 4a.

The values for CD8+ T-cells were significantly lower in Y-TNBS-Y group during 1st and 2nd weeks compared with TNBS group. No significant differences were found in the 3rd and 4th week, values being similar for both groups (Fig. 4b).

Values for CD4+ and CD8+ cells in group Y showed significant differences from the control group.


#### *Apoptosis Determination*

The percentage of apoptotic cells in large intestine in Y group and in the untreated controls groups were similar,



**Fig. 1.** Light micrograph of haematoxylin-eosin stained section from the large intestine of mice. (a) Large intestine of normal control mice without treatment, (b) large intestine of mice treated with TNBS (TNBS group) on week 4, (c) large intestine of Y-TNBS-Y group on week 4. Magnification 40 $\times$ .

while the number of apoptotic cells was decreased in the Y-TNBS-Y group compared with the TNBS group only for the 1st week. In the 2nd week the values were similar to



**Fig. 2.** Determination of the number of IgA producing cells in the large intestine by direct immunofluorescence assay. Values are the means of  $n=5 \pm SD$ .

\* $P < 0.001$  \*\* $P < 0.01$ .

□, Control; ■, Y; ▨, TNBS; ▩, Y-TNBS-Y.

those obtained for TNBS group. For the 3rd and 4th week values for Y-TNBS-Y group were significantly increased compared with the TNBS group. These results are showed in Fig. 5 and Fig. 6a & b.


## Discussion

The oral introduction of probiotics has been shown to reinforce the various lines of gut defence: immune exclusion, immune elimination, and immune regulation (Perdigón et al. 1995; Maldonado Galdeano et al. 2007). Probiotics also stimulate non-specific host resistance to microbial pathogens (Cobbato et al. 2008).

Normal responses in the gut are based on the production of IgA antibodies that perform the immunocclusion of microbes and antigens on the surface of the epithelium. These responses do not induce inflammation or tissue damage. In a previous work we demonstrated gut immunostimulation induced by yoghurt feeding (Perdigón et al. 1994).

IgA secretion is known to promote the gut immunological barrier and has been shown to be of great importance in the establishment of tolerance towards the indigenous microflora in a T-cell independent manner (Macpherson et al. 2000). In our laboratory we observed that dietary supplementation with yoghurt increased the number of IgA-secreting cells in the large intestine during the development of a colorectal carcinoma (Perdigón et al. 2002). The increase in local IgA levels resulting after probiotic ingestion may also contribute to the protective effect of gut mucosal against an IBD process (Malin et al. 1996).


In this paper we demonstrated through histological studies in a TNBS induced colitis model, that feeding with yoghurt decreased the number of infiltrative immune cells in the large intestine. We did not observed transmural



**Fig. 3.** (a) Microphotograph of IgA+ cells in colonic crypts of the large intestine of mice treated with TNBS, on the week 2 (b) Microphotograph of IgA+ cells in colonic crypts of the large intestine in the Y-TNBS-Y group on the week 2. Magnification 40 $\times$ .

injury, crypt cell hyperplasia or ulcerations (Fig. 1c) as found in the TNBS group (Fig. 1b) in relation to the control (Fig. 1a). We did not find hematological modifications in the group Y-TNBS-Y even after TNBS instillation in relation to the group TNBS (Table 1). The low values found for the Y-TNBS-Y group would show a great diminution of the inflammatory response induced by TNBS.

When we analysed the number of IgA secreting cells we observed a significant increase for the 2nd and 3rd week in the group Y-TNBS-Y compared with the TNBS and control groups and it was less significant in the group Y (Fig. 2, Fig. 3a & b). In a previous report (Perdigón et al. 1994) the influence of yoghurt feeding on the number of IgA cells was demonstrated. The increase in the IgA+ cells in the group Y-TNBS-Y could have contributed to the anti-inflammatory effect determined by histological studies due to the anti-inflammatory property attributed to the IgA (Iacson, 1982). In a previous work we observed a similar



**Fig. 4.** (a) Determination of the number CD4+ T cells in the large intestine by direct immunofluorescence assay. (b) Determination of the number CD8+ T cells in the large intestine. Values are the means of  $n=5 \pm \text{SD}$ .


\* $P < 0.001$  \*\* $P < 0.01$ .

□, Control; ■, Y; ▨, TNBS; ▩, Y-TNBS-Y.

effect of yoghurt with an enhancement in the IgA+ cells an experimental model colon carcinoma (Perdigón et al. 1998 & 2002). We believe that the strong stimulation induced by TNBS instillation induces a great inflammatory response with a high production of proinflammatory cytokines. This inflammatory response is not stimulated by yoghurt feeding which induced a clonal expansion change by proliferation of the IgA+ cell with an important increase in the number of these cells in the Y-TNBS-Y group, with a consequent diminution of such response.

During acute inflammatory episodes, the mucosal lining of the intestine displays a characteristic inflammatory infiltrate of mast cells, lymphocytes, macrophages, and activated neutrophils (Singh et al. 2001). Damage to the epithelial gut mucosa in IBD has been linked to elevated levels of effector immune cells such as activated CD4+ and CD8+ cytotoxic T cells, cytolytic intraepithelial lymphocytes (IELs), and perforin and granzyme-containing T cells (Muller et al. 1998).


There is considerable evidence that IBD patients have inappropriate T-cell responses to antigenic components of their own intestinal microbiota. Thus, IBD patients not only suffer from hyper-reactiveness towards their normal



**Fig. 5.** Determination of the number of apoptotic cells in the colonic crypts in the large intestine. Values are the means of  $n=3 \pm \text{SD}$ .

\* $P < 0.001$ .

□, Control; ■, Y; ▨, TNBS; ▩, Y-TNBS-Y.



**Fig. 6.** Apoptotic cells determined in histological slices of the large intestine on week 4 (a) Apoptotic cells in mice from the TNBS group (b) Apoptotic cells in mice from the Y-TNBS-Y group. Magnification 40 $\times$ .

intestinal microbiota but the reactivity of T cell populations driving inappropriate auto-immune reactions, this fact impairs the bacterial clearance. We determined that yoghurt feeding was effective by modulating the immune deregulation induced in IBD process. We found that TNBS administration produced an increase in CD4+ on weeks 1, 3 and 4 and in CD8+ T cells on weeks 1 and 2 in the large intestine, while in the Y-TNBS-Y group induced a diminution in the number of both T populations throughout the period assayed (Fig. 4a & b). We believe that TNBS instillation induces a strong inflammatory response with damage to the epithelial barrier, as a consequence, the immune cells as CD4+ and CD8+ increase and are activated to release proinflammatory cytokines increasing the bacterial translocation originate by disruption of the epithelium. This speculation allow us to explain the increase in CD4+ and CD8+ cells in the group TNBS where the great inflammatory response would be magnified by cytotoxic or cytolic activities of both T cells populations. When yoghurt was administrated we observed a diminution in the cellular infiltration of both T cells population, this fact would avoid the proinflammatory cytokines produced by CD4+ cells, or the cytotoxic effect mediated by CD8+ T cells. In this model yoghurt feeding induced normalization in the number of T cell, reaching values lower than the group Y, but similar to the values for the untreated control group. In group Y the number of CD4+ and CD8+ cells were enhanced in relation to the control values, we think that the effect of yoghurt administration is different in a normal host, perhaps due to the immune cells associated with the gut, are not receiving an inflammatory stimuli as occurs in IBD. The diminution in the CD8+ T population was also observed in a cancer colon model (Perdigón et al. 1998).

Intestinal tissue homeostasis is maintained by a balance between cell proliferation and cell death, and a loss of this equilibrium, is involved in pathogenic disease (Saikumar et al. 1999). In physiology condition, T cells become more susceptible to programmed cell death (apoptosis) once they are activated. This fact leads to the cell elimination, a necessary feature, to allow re-establishment of the non-inflamed state. There is evidence that T cells of the lamina propria from CD and UC patients are more resistant to apoptosis (Boirivant et al. 1999). In this experimental model of IBD we observed that feeding with yoghurt increased the number of apoptotic cells in large intestine (Fig. 5, 6); this increase was more significant toward the end of the period of yoghurt administration. These results agree with a previous work, where we showed that the dietary supplementation of yoghurt may play a role in modulating cell proliferation or apoptosis during the development of colorectal carcinoma (Rachid et al. 2002).

In the present paper we demonstrated that yoghurt consumption would be useful to alleviate IBD. The way by which yoghurt exerts such effect would be through the immune mechanisms, with an increased in IgA+ cells,

capable of modulating the inflammatory response with a diminution in CD4+ and CD8+ population and an increase in the apoptosis of the infiltrative immune cells.

This work was financially supported by grants from the Consejo de Investigaciones Universidad Nacional de Tucumán, Argentina (CIUNT) D/351 and from the Consejo de Investigaciones Científicas y Técnicas, Argentina (CONICET) PIP 5445.

## References

- Blumberg RS & Strober W** 2001 Prospects for research in inflammatory bowel disease. *The Journal of the American Association* **285** 643–647
- Boirivant M, Marini M, Di Felice G, Pronio AM, Montesani C, Tersigni R & Strober W** 1999 Lamina propria T cells in Crohn's disease and other gastrointestinal inflammation show defective CD2 pathway-induced apoptosis. *Gastroenterology* **116** 557–565
- Chin KW & Barrett KE** 1994 Mast cells are not essential to inflammation in murine model of colitis. *Digestive Diseases and Sciences* **39** 513–525
- Fiocchi C** 1998 Inflammatory bowel disease: etiology and pathogenesis. *Gastroenterology* **115** 182–205
- Fuss IJ, Marth T, Neurath MF, Pearlstein GR, Jain A & Strober W** 1999 Anti-interleukin 12 treatment regulates apoptosis of Th1 cells in experimental colitis in mice. *Gastroenterology* **117** 1078–1088
- Gobbato N, Maldonado Galdeano C & Perdigon G** 2008 Study of some of the mechanisms involved in the prevention against *Salmonella enteritidis* serovar *Typhimurium* infection by lactic acid bacteria. *Food and Agricultural Immunology* **19** 17–23
- Guarner F & Schaafsma G** 1998 Probiotics. *International Journal of Food Microbiology* **39** 237–238
- Isaacson P** 1982 Immunoperoxidase study of the secretory immunoglobulin system in colonic neoplasia. *Journal of Clinical Pathology* **35** 14–25
- Isolauri E** 2001 Probiotics in human disease. *The American Journal of Clinical Nutrition* **73** 1142S–1146S
- Isolauri E, Sütas Y, Kankaanpää P, Arvilommi H & Salminen S** 2001 Probiotics: effects on immunity. *The American journal of clinical nutrition* **73** 444S–450S
- Macpherson AJ, Gatto D, Sainsbury E, Harriman GR, Hengartner H & Zinkernagel RM** 2000 A primitive T cell-independent mechanism of intestinal mucosal IgA responses to commensal bacteria. *Science* **288** 2222–2226
- Madsen KL, Doyle JS, Jewell LD, Tavernini MM & Fedorak RN** 1999 *Lactobacillus* species prevents colitis in interleukin 10 gene-deficient mice. *Gastroenterology* **116** 1107–1114
- Maldonado Galdeano CM, de Moreno de LeBlanc A, Vinderola G, Bonet ME & Perdigón G** 2007 Proposed Model: Mechanisms of immunomodulation induced by probiotic bacteria. *Clinical and Vaccine Immunology* **14** 485–492
- Malin M, Suomalainen H, Saxelin M & Isolauri E** 1996 Promotion of IgA immune response in patients with Crohn's disease by oral bacteriotherapy with *Lactobacillus GG*. *Annals of Nutrition & Metabolism* **40** 137–145
- Müller S, Lory J, Corazza N, Griffiths GM, Z'graggen K, Mazzucchelli L, Kappeler A & Mueller C** 1998 Activated CD4+ and CD8+ cytotoxic cells are present in increased numbers in the intestinal mucosa from patients with active inflammatory bowel disease. *The American Journal of Pathology* **152** 261–268.
- Perdigón G, Alvarez S, Rachid M, Agüero G & Gobbato N** 1995 Immune system stimulation by probiotic. *Journal of Dairy Science* **78** 1597–1606
- Perdigón G, de Moreno de LeBlanc A, Valdez J & Rachid M** 2002 Role of yoghurt in the prevention of colon cancer. *European Journal of Clinical Nutrition* **56** S65–68

- Perdigón G, Rachid M, De Budeguer MV & Valdez JC** 1994 Effect of yogurt feeding on the small and large intestine associated lymphoid cells in mice. *Journal of Dairy Research* **61** 553–562
- Perdigón G, Valdez JC & Rachid M** 1998 Antitumor activity of yogurt: study of the possible immune mechanisms. *Journal of Dairy Research* **65** 129–138
- Pirzer U, Schänhaar A, Fleischer B, Hermann E & Meyer zum Büschenfelde KH** 1991 Reactivity of infiltrating T lymphocytes with microbial antigens in Crohn's disease. *Lancet* **338** 1238–1239
- Rachid MM, Gobbato NM, Valdéz JC, Vitalone HH & Perdigón G** 2002 Effect of yogurt on the inhibition of an intestinal carcinoma by increasing cellular apoptosis. *International Journal of Immunopathology and Pharmacology* **15** 209–216
- Saikumar P, Dong Z, Mikhailov V, Denton M, Weinberg JM & Venkatchalam MA** 1999 Apoptosis: definition, mechanisms, and relevance to disease. *The American Journal of Medicine* **107** 489–506.
- Sainte-Marie G** 1962 A paraffin embedding technique for studies employing immunofluorescence. *The Journal of Histochemistry and Cytochemistry* **10** 250–256
- Salminen S, Bouley C, Boutron-Ruault MC, Cummings JH, Franck A, Gibson GR, Isolauri E, Moreau MC, Roberfroid M & Rowland I** 1998 Functional food science and gastrointestinal physiology and function. *British Journal of Nutrition* **80** S147–171
- Shanahan F** 2001 Inflammatory bowel disease: immunodiagnostics, immunotherapeutics, and eotherapeutics. *Gastroenterology* **120** 622–635
- Singh B, Read S, Asseman C, Malmström V, Mottet C, Stephens LA, Stepankova R, Tlaskalova H & Powrie F** 2001 Control of intestinal inflammation by regulatory T cells. *Immunological Reviews* **182** 190–200
- Steidler L** 2001 Microbiological and immunological strategies for treatment of inflammatory bowel disease. *Microbes and infection* **3** 1157–1166